Citadel Advisors
AGRX

Citadel Advisors’s Agile Therapeutics AGRX Stock Holding History

Citadel Advisors’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-38
Closed -$16K – 14620
2022
Q1 		$16K Sell
38
-34
-47% -$21.7K ﹤0.01% 13308
2021
Q4 		$71K Sell
72
-75
-51% -$106K ﹤0.01% 13021
2021
Q3 		$282K Sell
147
-34
-19% -$77K ﹤0.01% 11186
2021
Q2 		$481K Buy
181
+75
+71% +$247K ﹤0.01% 10142
2021
Q1 		$442K Buy
106
+66
+165% +$357K ﹤0.01% 9958
2020
Q4 		$230K Sell
40
-5
-11% -$29.4K ﹤0.01% 9530
2020
Q3 		$275K Sell
45
-21
-32% -$120K ﹤0.01% 8276
2020
Q2 		$366K Buy
66
+29
+78% +$151K ﹤0.01% 7595
2020
Q1 		$137K Buy
+37
New +$212K ﹤0.01% 8373

Other funds holding AGRX

IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

Citadel Advisors's AGRX Position: Q1 2024 in Review

Citadel Advisors sold out of Agile Therapeutics (AGRX) in Q1 2024, closing a stake of 19,247 shares — an estimated $37.5K sold.

Citadel Advisors first reported a position in AGRX in Q4 2015 and held it in 13 quarters. The position peaked at $408K in Q1 2021. 1 fund tracked by Wall St. Rank holds AGRX as of Q1 2024.

  • Citadel Advisors reported no remaining Agile Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Citadel Advisors sold 19,247 Agile Therapeutics shares in Q1 2024, an estimated $37.5K.
  • Citadel Advisors first reported a position in Agile Therapeutics in Q4 2015 and held it in 13 quarters.
  • Citadel Advisors's Agile Therapeutics position peaked at $408K in Q1 2021.
  • 1 fund tracked by Wall St. Rank held Agile Therapeutics as of Q1 2024.

Based on Citadel Advisors's 13F filing for Q1 2024, filed 15 May 2024.